Menu
ÚHKT

Impaktované publikace

[1]

Wei, A.H.; Döhner, H.; Pocock, C.; Montesinos, P.; Afanasyev, B.; Dombret, H.; Ravandi, F.; Sayar, H.; Jang, J.-H.; Porkka, K.; Selleslag, D.; Sandhu, I.; Turgut, M.; Giai, V.; Ofran, Y.; Çakar, M.K.; de Sousa, A.B.; Rybka, J.; Frairia, C.; Borin, L.; Beltrami, G.; Čermák, J.; et al.

Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission

[rok vydání 2021, impact factor 91.245 ]

[2]

Pleyer, L.; Leisch, M.; Kourakli, A.; Padron, E.; Maciejewski, J.P.; Xicoy Cirici, B.; Kaivers, J.; Ungerstedt, J.; Heibl, S.; Patiou, P.; Hunter, A.M.; Mora, E.; Geissler, K.; Dimou, M.; Jimenez Lorenzo, M.-J.; Melchardt, T.; Egle, A.; Viniou, A.-N.; Patel, B.J.; Arnan, M.; Valent, P.; Roubakis, C.; Bernal del Castillo, T.; Galanopoulos, A.; Calabuig Muñoz, M.; Bonadies, N.; Medina de Almeida, A.; Cermak, J.; et al.

Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study

[rok vydání 2021, impact factor 18.959 ]

[3]

Kantarjian, H.M.; Thomas, X.G.; Dmoszynska, A.; Wierzbowska, A.; Mazur, G.; Mayer, J.; Cermak, J.; et al.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

[rok vydání 2013, impact factor 18.038 ]

[4]

Pfeilstöcker, M.; Tuechler, H.; Sanz, G.; Schanz, J.; Garcia-Manero, G.; Solé, F.; Bennett, J.M.; Bowen, D.; Fenaux, P.; Dreyfus, F.; Kantarjian, H.; Kuendgen, A.; Malcovati, L.; Cazzola, M.; Cermak, J.; Fonatsch, C.; Le Beau, M.M.; Slovak, M.L.; Levis, A.; Luebbert, M.; Maciejewski, J.; Machherndl-Spandl, S.; Magalhaes, S.M.; Miyazaki, Y.; Sekeres, M.A.; Sperr, W.R.; Stauder, R.; Tauro, S.; Valent, P.; Vallespi, T.; van de Loosdrecht, A.A.; Germing, U.; Haase, D.; Greenberg, P.L.

Time-dependent changes in mortality and transformation risk in MDS

[rok vydání 2016, impact factor 13.164 ]

[5]

Greenberg, P.L.; Tuechler, H.; Schanz, J.; Sanz, G.; Garcia-Manero, G.; Solé, F.; Bennett, J.M.; Bowen, D.; Fenaux, P.; Dreyfus, F.; Kantarjian, H.; Kuendgen, A.; Levis, A.; Malcovati, L.; Cazzola, M.; Cermak, J.; Fonatsch, C.; Le Beau, M.M.; Slovak, M.L.; Krieger, O.; Luebbert, M.; Maciejewski, J.; Magalhaes, S.M.; Miyazaki, Y.; Pfeilstöcker, M.; Sekeres, M.; Sperr, W.R.; Stauder, R.; Tauro, S.; Valent, P.; Vallespi, T.; van de Loosdrecht, A.A.; Germing, U.; Haase, D.

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

[rok vydání 2016, impact factor 13.164 ]

[6]

Basak, A.; Hancarova, M.; Ulirsch, J.C.; Balci, T.B.; Trkova, M.; Pelisek, M.; Vlckova, M.; Muzikova, K.; Cermak, J.; Trka, J.; Dyment, D.A.; Orkin, S.H.; Daly, M.J.; Sedlacek, Z.; Sankaran, V.G.

BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations

[rok vydání 2015, impact factor 12.575 ]

[7]

da Silva-Coelho, P.; Kroeze, L.I.; Yoshida, K.; Koorenhof-Scheele, T.N.; Knops, R.; van de Locht, L.T.; de Graaf, A.O.; Massop, M.; Sandmann, S.; Dugas, M.; Stevens-Kroef, M.J.; Cermak, J.; et al.

Clonal evolution in myelodysplastic syndromes

[rok vydání 2017, impact factor 12.353 ]

[8]

Della Porta, M.G.; Tuechler, H.; Malcovati, L.; Schanz, J.; Sanz, G.; Garcia-Manero, G.; Solé, F.; Bennett, J.M.; Bowen, D.; Fenaux, P.; Dreyfus, F.; Kantarjian, H.; Kuendgen, A.; Levis, A.; Cermak, J.; Fonatsch, C.; Le Beau, M.M.; Slovak, M.L.; Krieger, O.; Luebbert, M.; Maciejewski, J.; Magalhaes, S.M.; Miyazaki, Y.; Pfeilstöcker, M.; Sekeres, M.A.; Sperr, W.R.; Stauder, R.; Tauro, S.; Valent, P.; Vallespi, T.; van de Loosdrecht, A.A.; Germing, U.; Haase, D.; Greenberg, P.L.; Cazzola, M.

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R): a study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)

[rok vydání 2015, impact factor 12.104 ]

[9]

Hoeks, M.; Bagguley, T.; van Marrewijk, C.; Smith, A.; Bowen, D.; Culligan, D.; Kolade, S.; Symeonidis, A.; Garelius, H.; Spanoudakis, M.; Langemeijer, S.; Roelofs, R.; Wiegerinck, E.; Tatic, A.; Killick, S.; Panagiotidis, P.; Stanca, O.; Hellström-Lindberg, E.; Cermak, J.; et al.

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

[rok vydání 2020, impact factor 11.528 ]

[10]

Germing, U.; Lauseker, M.; Hildebrandt, B.; Symeonidis, A.; Cermak, J.; Fenaux, P.; Kelaidi, C.; Pfeilstöcker, M.; Nösslinger, T.; Sekeres, M.; Maciejewski, J.; Haase, D.; Schanz, J.; Seymour, J.; Kenealy, M.; Weide, R.; Lübbert, M.; Platzbecker, U.; Valent, P.; Götze, K.; Stauder, R.; Blum, S.; Kreuzer, K.-A.; Schlenk, R.; Ganser, A.; Hofmann, W.-K.; Aul, C.; Krieger, O.; Kündgen, A.; Haas, R.; Hasford, J.; Giagounidis, A.

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study

[rok vydání 2012, impact factor 10.164 ]

[11]

Curik, N.; Burda, P.; Vargova, K.; Pospisil, V.; Belickova, M.; Vlckova, P.; Savvulidi, F.; Necas, E.; Hajkova, H.; Haskovec, C.; Cermak, J.; Krivjanska, M.; Trneny, M.; Laslo, P.; Jonasova, A.; Stopka, T.

5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity

[rok vydání 2012, impact factor 10.164 ]

[12]

Kramarzova, K.; Stuchly, J.; Willasch, A.; Gruhn, B.; Schwarz, J.; Cermak, J.; Machova-Polakova, K.; Fuchs, O.; Stary, J.; Trka, J.; Boublikova, L.

Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences

[rok vydání 2012, impact factor 10.164 ]

[13]

Stauder, R.; Yu, G.; Koinig, K.A.; Bagguley, T.; Fenaux, P.; Symeonidis, A.; Sanz, G.; Cermak, J.; et al.

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

[rok vydání 2018, impact factor 9.944 ]

[14]

de Swart, L.; Crouch, S.; Hoeks, M.; Smith, A.; Langemeijer, S.; Fenaux, P.; Symeonidis, A.; Čermák, J.; et al.

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

[rok vydání 2020, impact factor 9.941 ]

[15]

Hoeks, M.; Yu, G.; Langemeijer, S.; Crouch, S.; de Swart, L.; Fenaux, P.; Symeonidis, A.; Čermák, J.; et al.

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry

[rok vydání 2020, impact factor 9.941 ]

[16]

de Witte, T.; Malcovati, L.; Fenaux, P.; Bowen, D.; Symeonidis, A.; Mittelman, M.; Stauder, R.; Sanz, G.; Čermák, J.; et al.

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome: the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective

[rok vydání 2020, impact factor 9.941 ]

[17]

Malcovati, L.; Hellström-Lindberg, E.; Bowen, D.; Ades, L.; Čermák, J.; Del Canizo, C.; Della Porta, M.G.; Fenaux, P.; Gattermann, N.; Germing, U.; Jansen, J.H.; Mittelman, M.; Mufti, G.; Platzbecker, U.; Sanz, G.F.; Selleslag, D.; Skov-Holm, M.; Stauder, R.; Symeonidis, A.; Van De Loosdrecht, A.A.; De Witte, T.; Cazzola, M.

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

[rok vydání 2013, impact factor 9.775 ]

[18]

Greenberg, P.L.; Tuechler, H.; Schanz, J.; Sanz, G.; Garcia-Manero, G.; Solé, F.; Bennet; J.M.; Bowen, D.; Fenaux, P.; Dreyfus, F.; Kantarjian, H.; Kuendgen, A.; Levis, A.; Malcovati, L.; Cazzola, M.; Cermak, J.; Fonatsch, C.; Le Beau, M.M.; Slovak, M.L.; Krieger, O.; Luebbert, M.; Maciejewski, J.; Magalhaes, S.M.M.; Miyazaki, Y.; Pfeilstöcker, M.; Sekeres, M.; Sperr, W.R.; Stauder, R.; Tauro, S.; Valent, P.; Vallespi, T.; Van De Loosdrecht, A.A.; Germing, U.; Haase, D.

Revised international prognostic scoring system for myelodysplastic syndromes

[rok vydání 2012, impact factor 9.060 ]

[19]

Cermak, J.; Key, N.S.; Bach, R.R.; Balla, J.; Jacob, H.S.; Vercellotti, G.M.

C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor

[rok vydání 2006, impact factor 8.061]

[20]

de Swart, L.; Reiniers, C.; Bagguley, T.; van Marrewijk, C.; Bowen, D.; Hellström-Lindberg, E.; Tatic, A.; Symeonidis, A.; Huls, G.; Cermak, J.; et al.

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes

[rok vydání 2018, impact factor 7.570 ]